272 related articles for article (PubMed ID: 26498137)
21. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
Bae SY; Hong JY; Lee HJ; Park HJ; Lee SK
Oncotarget; 2015 Apr; 6(12):10146-60. PubMed ID: 25760142
[TBL] [Abstract][Full Text] [Related]
22. Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines.
Baharuddin P; Satar N; Fakiruddin KS; Zakaria N; Lim MN; Yusoff NM; Zakaria Z; Yahaya BH
Oncol Rep; 2016 Jan; 35(1):13-25. PubMed ID: 26531053
[TBL] [Abstract][Full Text] [Related]
23. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
Wu F; Li J; Jang C; Wang J; Xiong J
Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
[TBL] [Abstract][Full Text] [Related]
24. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
Konen JM; Rodriguez BL; Padhye A; Ochieng JK; Gibson L; Diao L; Fowlkes NW; Fradette JJ; Peng DH; Cardnell RJ; Kovacs JJ; Wang J; Byers LA; Gibbons DL
Cancer Res; 2021 Mar; 81(5):1398-1412. PubMed ID: 33402388
[TBL] [Abstract][Full Text] [Related]
25. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
Ishikawa M; Sonobe M; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Date H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S467-76. PubMed ID: 23242819
[TBL] [Abstract][Full Text] [Related]
26. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
27. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
Wang Y; Xia H; Zhuang Z; Miao L; Chen X; Cai H
Cell Death Dis; 2014 May; 5(5):e1227. PubMed ID: 24832599
[TBL] [Abstract][Full Text] [Related]
28. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer.
Avilla E; Guarino V; Visciano C; Liotti F; Svelto M; Krishnamoorthy G; Franco R; Melillo RM
Cancer Res; 2011 Mar; 71(5):1792-804. PubMed ID: 21343401
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
30. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
31. Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism.
Huang JS; Cho CY; Hong CC; Yan MD; Hsieh MC; Lay JD; Lai GM; Cheng AL; Chuang SE
Free Radic Biol Med; 2013 Dec; 65():1246-1256. PubMed ID: 24064382
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS
Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347
[TBL] [Abstract][Full Text] [Related]
33. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Scherschinski L; Prem M; Kremenetskaia I; Tinhofer I; Vajkoczy P; Karbe AG; Onken JS
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055167
[TBL] [Abstract][Full Text] [Related]
34. Anti-cancer effect of tectochrysin in NSCLC cells through overexpression of death receptor and inactivation of STAT3.
Oh SB; Hwang CJ; Song SY; Jung YY; Yun HM; Sok CH; Sung HC; Yi JM; Park DH; Ham YW; Han SB; Hwang BY; Hong JT
Cancer Lett; 2014 Oct; 353(1):95-103. PubMed ID: 25083589
[TBL] [Abstract][Full Text] [Related]
35. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL.
Abboud-Jarrous G; Priya S; Maimon A; Fischman S; Cohen-Elisha M; Czerninski R; Burstyn-Cohen T
Oncotarget; 2017 Feb; 8(8):13986-14002. PubMed ID: 28118606
[TBL] [Abstract][Full Text] [Related]
36. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
37. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
[TBL] [Abstract][Full Text] [Related]
38. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
[TBL] [Abstract][Full Text] [Related]
39. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
40. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]